Vytorin Uses
Links shared publicly online about this topic
MediGuard - Vytorin View
mediguard.org — “MediGuard - Vytorin View” View full resource at mediguard.org
Most Recently Shared on November 24, 2010 at 1:17 pm By:
MediGuard.org Health Organization
Approx 15% of #vytorin users experiencing muscle pain/cramps: http://tinyurl.com/ybhm37o
FDA to Explore Possible Vytorin-Cancer Link
webmd.com — “The FDA is investigating a report from the SEAS trial of a possible association between use of the drug Vytorin and increased cancer risk.” View full resource at webmd.com
Most Recently Shared on August 22, 2008 at 2:22 am By:
WebMD Health News FDA to Explore Possible Vytorin-Cancer Link: The FDA is investigati.. http://tinyurl.com/6nqy3r
FDA allows Vytorin labeling for use in kidney disease, but not new indication
nephrologynews.com — “FDA did not approve a new indication for Vytorin or for Zetia” View full resource at nephrologynews.com
Most Recently Shared on January 27, 2012 at 3:56 pm By:
Nephrology News Health News and Nephrology
FDA allows Vytorin labeling for use in kidney disease, but not new indication http://t.co/oMlX4LMD
FDA: Vytorin Unlikely to Up Cancer Risk
tweetmeme.com — “The FDA has backed off a 2008 statement describing a possible link between use of the cholesterol-lowering drug Vytorin and cancer, saying any connection is unlikely but shouldn't be ruled out.” View full resource at tweetmeme.com
Most Recently Shared on December 23, 2009 at 3:48 pm By:
Healthcare TweetMeme Health Social Media
FDA: Vytorin Unlikely to Up Cancer Risk http://retwt.me/1Lddk (via @rashmigupta2100)
FDA: Vytorin Unlikely to Up Cancer Risk
tweetmeme.com — “The FDA has backed off a 2008 statement describing a possible link between use of the cholesterol-lowering drug Vytorin and cancer, saying any connection is unlikely but shouldn't be ruled out.” View full resource at tweetmeme.com
Most Recently Shared on December 23, 2009 at 2:50 am By:
Healthcare TweetMeme Health Social Media
FDA: Vytorin Unlikely to Up Cancer Risk http://retwt.me/1LcGZ (via @WellnessInfo)
Vytorin May Lose Preferred Status in Medicare Plans - Health Blog - WSJ
blogs.wsj.com — “Prescriptions are already falling for Vytorin in the wake of long-awaited test results that showed it wasn’t better than a generic statin in slowing hardening of the arteries, as measured by ultrasound. But the worst may be yet to come, if Medicare drug plans use the results to move Vytorin [...]” View full resource at blogs.wsj.com
Most Recently Shared on April 22, 2010 at 2:16 pm By:
Healthcare Channel Health Site
In 2008, The HCC first said that co-pays on Vytorin would increase due to the controversies http://tinyurl.com/2fnvtaz @WSJHealthBlog
Comments of using Vytorin - 10MG;20MG (study 6067508) - eHealthMe.com
ehealthme.com — “Does vytorin cause osteoarthrtis” View full resource at ehealthme.com
Most Recently Shared on March 16, 2012 at 5:28 am By:
Does vytorin cause osteoarthrtis http://t.co/GGAGJZqW
Study Finds No Connection Between Vytorin, Cancer - Health News | Current Health News | Medical News - FOXNews.com
foxnews.com — “Study Finds No Connection Between Vytorin, Cancer, New research into a possible link between a cholesterol-reducing drug and cancer concluded there was no proof to establish a connection, but other doctors warned that it should be used more carefully.” View full resource at foxnews.com
Most Recently Shared on September 2, 2008 at 5:55 pm By:
Leigh Ann Otte Health Magazine
Check out these headlines on the same Vytorin/cancer study: http://snipr.com/3m9xp - http://snipr.com/3m9xi
Follow-Up to the August 2008 Early Communication About an Ongoing Safety Review of Ezetimibe/Simvastatin (marketed as Vytorin), Simvastatin (marketed as Zocor) and Ezetimibe (marketed as Zetia) - FDA Investigates a Report from the SEAS Trial
fda.gov — “In august 2008, the u.s. food and drug administration (fda) issued an early communication describing a possible association between the use of vytorin – a combination of simvastatin (zocor) and ezetimibe (zetia) – and an increased risk of cancer and cancer-related death compared to placebo.” View full resource at fda.gov
Most Recently Shared on December 22, 2009 at 4:31 pm By:
eyeonfda Pharma and Health Lawyer
RT @FDA_Drug_Info: Follow-Up to the Aug. 2008 Early Communication on Vytorin, Zetia, Zocor and the SEAS Trial. http://bit.ly/FU_SEAS
FDA Restricts Use of Cholesterol-Lowering Drug - - TIME Healthland
healthland.time.com — “The Food and Drug Administration (FDA) on Wednesday restricted the use of high doses of the cholesterol-lowering drug simvastatin, which is sold in generic forms and under the brand names Zocor and Vytorin, because of concerns over muscle problems associated with the drug.” View full resource at healthland.time.com
Most Recently Shared on June 9, 2011 at 8:04 pm By:
HealthIT Policy Health News and Health IT
RT @TimeHealthland: FDA Restricts Use of High Doses of Cholesterol-Lowering Drug Zocor http://ti.me/kcw6iw
RxEconsult, LLC - Vytorin (ezetimibe/simvastatin) for cholesterol reduction
rxeconsult.com — “RxEconsult, LLC - Vytorin (ezetimibe/simvastatin) for cholesterol reduction” View full resource at rxeconsult.com
Most Recently Shared on September 20, 2011 at 11:58 am By:
RxEconsult. If you are in need of healthcare services or information, please visit RxEconsult.
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Dr. Ogbru has written several journal articles. In 1997, he shared an award from the American Journal of Pain Management for Outstanding Contribution to the Interdisciplinary Pain Management Literature. Over the last 12 years Dr. Ogbru has held several roles in the pharmaceutical industry, including Director of Global Medical Information and Communication." /> Ome Ogbru, PharmD Active Health Library, Doctor, Pharmacist, and PharmD
Merck’s cholesterol lowering drug gets FDA panel’s vote
news-medical.net — “A health advisors’ panel have unanimously backed the use of Merck & Co's cholesterol-lowering drug Vytorin for preventing stroke and other heart problems in patients with chronic kidney disease, but only in those patients not yet on dialysis. The panel voted 16-0 during a meeting today in Silver Spring, Maryland.” View full resource at news-medical.net
Most Recently Shared on November 4, 2011 at 12:49 am By:
Merck’s cholesterol lowering drug gets FDA panel’s vote: A health advisors’ panel have unanimously backed the us... http://t.co/G2OpFf7N
FDA Restricts Use of Cholesterol-Lowering Drug - - TIME Healthland
healthland.time.com — “The Food and Drug Administration (FDA) on Wednesday restricted the use of high doses of the cholesterol-lowering drug simvastatin, which is sold in generic forms and under the brand names Zocor and Vytorin, because of concerns over muscle problems associated with the drug.” View full resource at healthland.time.com
Most Recently Shared on June 9, 2011 at 9:49 pm By:
FDA restricts using high doses of Zocor, a popular cholesterol drug | http://ti.me/l3T8G4
The Top 3 resources shared on this topic. More resources.
Key stats and trends about this topic
Related WisdomCards
Related Health Centers
Featuring the top 3 experts for this topic
-
MediGuard.org
Live health insights from 2.5+ million users of MediGuard, the easiest way to get safety alerts and recalls for your medicines.
-
WebMD_News
The leading source for trustworthy and timely health news and information.
-
Nephrology News
Your resource for the latest developments in renal care since 1987.
Advertisement
